Skip to main content
. 2018 Jul 6;2018:bcr2018225039. doi: 10.1136/bcr-2018-225039

Table 2.

Literature review

Study number Authors Presenting symptoms Treatment Outcome
1 Smallridge et al5 Asymptomatic. DES.
Bilateral orchidectomy.
TURP.
ERT.
Cyclophosphamide.
5-FU.
Radiological progression of metastatic disease.
2 Szentirmai et al6 Lethargy. None. Died in 2 weeks.
3 Tandon and Rizvi7 Unknown. Goserelin.
Leuprolide.
Hypocalcaemic on discharge.
4 Fokkema et al8 Lethargy. Leuprorelin.
Bicalutamide.
Died in 4 months.
5 Rizzo et al9 Lethargy. ADT. Died in 2 months.
6 Pusulari et al10 Back pain and fatigue. None. Unknown.
7 Yener et al11 Tetany and anorexia. TURP.
Goserelin.
Bicalutamide.
Eucalcaemic after 12 weeks.
8 Riveros et al12 Bone pain. ADT.
Docetaxel.
Mitoxantrone.
Abiraterone.
Zoledronic acid.
Died in 3 weeks.
9 Lim et al13 Seizures. Calcitriol. Unknown.
10 Kabadi15 Back pain. Prostate resection.
Bilateral orchidectomy.
DES.
ERT.
Calcium and phosphorous normalised.
11 Kukreja et al14 Not mentioned. Calcium and magnesium supplementation. Unknown.

5-FU, 5-flourouracil; ADT, androgen deprivation therapy; DES, diethylstilbestrol; ERT, external radiotherapy; TURP, transurethral resection of prostate.